Literature DB >> 18503630

Tissue factor pathway inhibitor-gamma is an active alternatively spliced form of tissue factor pathway inhibitor present in mice but not in humans.

S A Maroney1, J P Ferrel, M L Collins, A E Mast.   

Abstract

BACKGROUND: Tissue factor pathway inhibitor (TFPI) is a potent inhibitor of tissue factor procoagulant activity produced as two alternatively spliced isoforms, TFPIalpha and TFPIbeta, which differ in domain structure and mechanism for cell surface association. 3' Rapid amplification of cDNA ends was used to search for new TFPI isoforms. TFPIgamma, a new alternatively spliced form of TFPI, was identified and characterized.
METHODS: The tissue expression, cell surface association and anticoagulant activity of TFPIgamma were characterized and compared to those of TFPIalpha and TFPIbeta through studies of mouse and human tissues and expression of recombinant proteins in Chinese hamster ovary (CHO) cells.
RESULTS: TFPIgamma is produced by alternative splicing using the same 5'-splice donor site as TFPIbeta and a 3'-splice acceptor site 276 nucleotides beyond the stop codon of TFPIbeta in exon 8. The resulting protein has the first two Kunitz domains connected to an 18 amino acid C-terminal region specific to TFPIgamma. TFPIgamma mRNA is differentially produced in mouse tissues but is not encoded within the human TFPI gene. When expressed in CHO cells, TFPIgamma is secreted into conditioned media and effectively inhibits tissue factor procoagulant activity.
CONCLUSIONS: TFPIgamma is a third alternatively spliced form of TFPI that is widely expressed in mouse tissues but not made by human tissues. It contains the first two Kunitz domains and is a secreted, rather than a cell surface-associated, protein. It is a functional anticoagulant and may partially explain the resistance of mice to coagulopathy in tissue factor-mediated models of disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18503630      PMCID: PMC3549614          DOI: 10.1111/j.1538-7836.2008.03033.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  35 in total

1.  Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody.

Authors:  R A Fleck; L V Rao; S I Rapaport; N Varki
Journal:  Thromb Res       Date:  1990-07-15       Impact factor: 3.944

2.  Role for the Kunitz-3 domain of tissue factor pathway inhibitor-alpha in cell surface binding.

Authors:  Orlando Piro; George J Broze
Journal:  Circulation       Date:  2004-11-22       Impact factor: 29.690

Review 3.  Alternative splicing and RNA selection pressure--evolutionary consequences for eukaryotic genomes.

Authors:  Yi Xing; Christopher Lee
Journal:  Nat Rev Genet       Date:  2006-06-13       Impact factor: 53.242

4.  Tissue-specific hemostasis: role of tissue factor.

Authors:  N Mackman
Journal:  J Thromb Haemost       Date:  2007-12-13       Impact factor: 5.824

5.  A balance between tissue factor and tissue factor pathway inhibitor is required for embryonic development and hemostasis in adult mice.

Authors:  Brian Pedersen; Todd Holscher; Yuichiro Sato; Rafal Pawlinski; Nigel Mackman
Journal:  Blood       Date:  2004-12-14       Impact factor: 22.113

6.  A GPI-anchored co-receptor for tissue factor pathway inhibitor controls its intracellular trafficking and cell surface expression.

Authors:  S A Maroney; A C Cunningham; J Ferrel; R Hu; S Haberichter; C M Mansbach; R A Brodsky; D J Dietzen; A E Mast
Journal:  J Thromb Haemost       Date:  2006-05       Impact factor: 5.824

7.  Active tissue factor pathway inhibitor is expressed on the surface of coated platelets.

Authors:  Susan A Maroney; Sandra L Haberichter; Paul Friese; Maureen L Collins; Josephine P Ferrel; George L Dale; Alan E Mast
Journal:  Blood       Date:  2006-11-02       Impact factor: 22.113

8.  Immunohistochemical detection of tissue factor (TF) on paraffin sections of routinely fixed human tissue.

Authors:  C Flössel; T Luther; M Müller; S Albrecht; M Kasper
Journal:  Histochemistry       Date:  1994-07

Review 9.  Tissue factor, coagulation proteases, and protease-activated receptors in endotoxemia and sepsis.

Authors:  Rafal Pawlinski; Nigel Mackman
Journal:  Crit Care Med       Date:  2004-05       Impact factor: 7.598

10.  Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor.

Authors:  T J Girard; L A Warren; W F Novotny; K M Likert; S G Brown; J P Miletich; G J Broze
Journal:  Nature       Date:  1989-04-06       Impact factor: 49.962

View more
  21 in total

1.  Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases.

Authors:  Steffen Massberg; Lenka Grahl; Marie-Luise von Bruehl; Davit Manukyan; Susanne Pfeiler; Christian Goosmann; Volker Brinkmann; Michael Lorenz; Kiril Bidzhekov; Avinash B Khandagale; Ildiko Konrad; Elisabeth Kennerknecht; Katja Reges; Stefan Holdenrieder; Siegmund Braun; Christoph Reinhardt; Michael Spannagl; Klaus T Preissner; Bernd Engelmann
Journal:  Nat Med       Date:  2010-08-01       Impact factor: 53.440

2.  Re-evaluation of mouse tissue factor pathway inhibitor and comparison of mouse and human tissue factor pathway inhibitor physiology.

Authors:  T J Girard; K Grunz; N M Lasky; J P Malone; G J Broze
Journal:  J Thromb Haemost       Date:  2018-10-22       Impact factor: 5.824

3.  Tissue factor pathway inhibitor primes monocytes for antiphospholipid antibody-induced thrombosis.

Authors:  Nadine Müller-Calleja; Anne Hollerbach; Svenja Ritter; Denise G Pedrosa; Dennis Strand; Claudine Graf; Christoph Reinhardt; Susanne Strand; Philippe Poncelet; John H Griffin; Karl J Lackner; Wolfram Ruf
Journal:  Blood       Date:  2019-08-21       Impact factor: 22.113

Review 4.  Biology of tissue factor pathway inhibitor.

Authors:  Jeremy P Wood; Paul E R Ellery; Susan A Maroney; Alan E Mast
Journal:  Blood       Date:  2014-03-11       Impact factor: 22.113

Review 5.  Platelet tissue factor pathway inhibitor modulates intravascular coagulation.

Authors:  Susan A Maroney; Alan E Mast
Journal:  Thromb Res       Date:  2012-03-17       Impact factor: 3.944

6.  Maintaining extraembryonic expression allows generation of mice with severe tissue factor pathway inhibitor deficiency.

Authors:  Michelle M Castillo; Qiuhui Yang; Min Zhan; Amy Y Pan; Michael W Lawlor; Alan E Mast; Rashmi Sood
Journal:  Blood Adv       Date:  2019-02-12

Review 7.  Alternatively spliced tissue factor pathway inhibitor: functional implications.

Authors:  Alan E Mast
Journal:  Front Biosci (Schol Ed)       Date:  2011-06-01

Review 8.  Alternatively spliced isoforms of tissue factor pathway inhibitor.

Authors:  Susan A Maroney; Paul E Ellery; Alan E Mast
Journal:  Thromb Res       Date:  2010-02-21       Impact factor: 3.944

9.  Temporal expression of alternatively spliced forms of tissue factor pathway inhibitor in mice.

Authors:  S A Maroney; J P Ferrel; S Pan; T A White; R D Simari; J H McVey; A E Mast
Journal:  J Thromb Haemost       Date:  2009-04-24       Impact factor: 5.824

Review 10.  Tissue Factor Pathway Inhibitor: Multiple Anticoagulant Activities for a Single Protein.

Authors:  Alan E Mast
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-11-24       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.